- Home
- CLB vs AURA Comparison
CLB vs AURA Comparison
Compare CLB & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- AURA
- Stock Information
- Founded
- CLB 1936
- AURA 2007
- Country
- CLB United States
- AURA United States
- Employees
- CLB N/A
- AURA N/A
- Industry
- CLB
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- AURA Health Care
- Exchange
- CLB Nasdaq
- AURA Nasdaq
- Market Cap
- CLB 482.5M
- AURA 396.8M
- IPO Year
- CLB 1995
- AURA 2021
- Fundamental
- Price
- CLB $12.04
- AURA $5.76
- Analyst Decision
- CLB Hold
- AURA Strong Buy
- Analyst Count
- CLB 2
- AURA 7
- Target Price
- CLB $12.50
- AURA $22.29
- AVG Volume (30 Days)
- CLB 496.6K
- AURA 283.0K
- Earning Date
- CLB 10-22-2025
- AURA 11-11-2025
- Dividend Yield
- CLB 0.34%
- AURA N/A
- EPS Growth
- CLB 23.99
- AURA N/A
- EPS
- CLB 0.62
- AURA N/A
- Revenue
- CLB $517,378,000.00
- AURA N/A
- Revenue This Year
- CLB N/A
- AURA N/A
- Revenue Next Year
- CLB $2.23
- AURA N/A
- P/E Ratio
- CLB $19.22
- AURA N/A
- Revenue Growth
- CLB 0.70
- AURA N/A
- 52 Week Low
- CLB $9.72
- AURA $4.35
- 52 Week High
- CLB $21.83
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- CLB 49.28
- AURA 37.10
- Support Level
- CLB $11.98
- AURA $5.93
- Resistance Level
- CLB $12.79
- AURA $6.28
- Average True Range (ATR)
- CLB 0.50
- AURA 0.26
- MACD
- CLB -0.08
- AURA -0.02
- Stochastic Oscillator
- CLB 18.84
- AURA 5.22
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.